Modality
siRNA
MOA
IL-17i
Target
USP1
Pathway
Wnt
DLBCLSchizophrenia
Development Pipeline
Preclinical
~Feb 2014
→ ~May 2015
Phase 1
~Aug 2015
→ ~Nov 2016
Phase 2
Feb 2017
→ Oct 2030
Phase 2Current
NCT03244745
2,112 pts·Schizophrenia
2017-02→2030-10·Completed
NCT04798091
2,717 pts·Schizophrenia
2023-09→2028-04·Not yet recruiting
4,829 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-04-202.1y awayPh2 Data· Schizophrenia
2030-10-064.5y awayPh2 Data· Schizophrenia
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2
Complet…
P2
Not yet…
Catalysts
Ph2 Data
2028-04-20 · 2.1y away
Schizophrenia
Ph2 Data
2030-10-06 · 4.5y away
Schizophrenia
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03244745 | Phase 2 | Schizophrenia | Completed | 2112 | SRI-4 |
| NCT04798091 | Phase 2 | Schizophrenia | Not yet recr... | 2717 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-3458 | Argenx | Preclinical | RET | |
| Nidaratamab | Krystal Biotech | Preclinical | RET | |
| Doxazasiran | Axsome | Phase 1 | TIM-3 | |
| Tirarelsin | TG Therapeutics | NDA/BLA | CD19 | |
| Nidasacituzumab | Day One Bio | Phase 3 | TIGIT |